‌

‌
‌
‌
‌

‌

‌

‌
‌
‌

‌

‌
‌
‌

‌

‌

‌
‌
‌

‌

‌
‌
‌

Ramitax (RAMELTEON)

brandsClassRamitax commonly prescribed forHow Ramitax worksHow long until Ramitax worksNotable Side EffectsLife Threatening Side Effectsweight gainsedationWhat to do about Ramitax side effectsusual dosage rangeDosage Formslong term usehabit formingRenal ImpairmentHepatic ImpairmentCardiac ImpairmentElderlyChildren and AdolescentsPregnancyBreast Feeding

THERAPEUTICS

brands

  • Ramitax

Class

  • Neuroscience-based Nomenclature: melatonin receptor agonist (Mel-RA)
  • Melatonin 1 and 2 receptor agonist

Ramitax commonly prescribed for

(Bold for FDA approved)

• Insomnia (difficulty with sleep onset)
• Primary insomnia
• Chronic insomnia
• Transient insomnia
• Insomnia associated with shift work, jet lag, or circadian rhythm disturbances

How Ramitax works

• Binds selectively to melatonin 1 and melatonin 2 receptors as a full agonist

How long until Ramitax works

• Generally takes effect in less than an hour

SIDE EFFECTS

Notable Side Effects

• Sedation

• Dizziness

• Fatigue

• Headache

Life Threatening Side Effects

• Respiratory depression, especially when taken with other CNS depressants in overdose

• Rare angioedema

weight gain

unusual

unusual

sedation

common

common

What to do about Ramitax side effects

• Wait

• To avoid problems with memory, only take ramelteon if planning to have a full night’s sleep

• Lower the dose

• Switch to a non-benzodiazepine sedative hypnotic

DOSING AND USE

usual dosage range

• 8 mg at bedtime

Dosage Forms

• Tablet 8 mg

long term use

• No reports of dependence, tolerance, or abuse liability

• Not restricted to short-term use but few long-term studies

habit forming

• No

SPECIAL POPULATIONS

Renal Impairment

• Dose adjustment not generally necessary

Hepatic Impairment

• Use with caution in patients with moderate hepatic impairment

• Not recommended for use in patients with severe impairment

Cardiac Impairment

• Dosage adjustment may not be necessary

Elderly

• No adjustment necessary

• Greater absorption and higher plasma drug concentrations but no increase in side effects

Children and Adolescents

• Safety and efficacy have not been established

Pregnancy

• Effective June 30, 2015, the FDA requires changes to the content and format of pregnancy and lactation information in prescription drug labels, including the elimination of the pregnancy letter categories; the Pregnancy and Lactation Labeling Rule (PLLR or final rule) applies only to prescription drugs and will be phased in gradually for drugs approved on or after June 30, 2001

• Controlled studies have not been conducted in pregnant women

Breast Feeding

• Unknown if ramelteon is secreted in human breast milk, but all psychotropics are assumed to be secreted in breast milk

• Recommended either to discontinue drug or bottle feed

Based on data Published online by Cambridge University Press

Compiled by Dr. Jash Ajmera